help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradbeer, J. N.
Right arrow Articles by Loveridge, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradbeer, J. N.
Right arrow Articles by Loveridge, N.

Journal of Clinical Endocrinology & Metabolism, Vol 67, 1237-1243, Copyright © 1988 by Endocrine Society

ARTICLES

The metatarsal cytochemical bioassay of parathyroid hormone: validation, specificity, and application to the study of pseudohypoparathyroidism type I

JN Bradbeer, J Dunham, JA Fischer, C Nagant de Deuxchaisnes and N Loveridge
Division of Cellular Biology, Kennedy Institute of Rheumatology, London, United Kingdom.

The most sensitive method for assaying the bioactivity of PTH in unextracted plasma is the renal cytochemical bioassay. However, PTH acts on bone as well as kidney and clinical studies have suggested that the actions of circulating PTH level may be different at the two sites. We developed cytochemical bioassay for PTH based on the stimulation of glucose 6-phosphate dehydrogenase activity in the hypertrophic chondrocytes of the growth plate and the osteoblasts lining the metaphyseal trabeculae of rat metatarsal bones. The index of precision was 0.14 +/- 0.02 (SE) and the interassay variation was 31%. With this assay, plasma bioactive PTH levels in normal subjects and patients with primary hyperparathyroidism ranged from 0.5-18 ng/L and from 27-850 ng/L, respectively. Studies of patients with pseudohypoparathyroidism type I indicated that plasma PTH bioactivity in such patients is greater in the metatarsal bioassay than in the renal bioassay; no such differences were found in normal subjects or patients with primary hyperparathyroidism.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. M. Jan de Beur, C.-L. Ding, M. C. LaBuda, T. B. Usdin, and M. A. Levine
Pseudohypoparathyroidism 1b: Exclusion of Parathyroid Hormone and Its Receptors as Candidate Disease Genes
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2239 - 2246.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Nakaoka, T. Sugimoto, T. Kobayashi, T. Yamaguchi, A. Kobayashi, and K. Chihara
Prediction of Bone Mass Change after Parathyroidectomy in Patients with Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1901 - 1907.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society